Login to Your Account

Amylin Seeks $92M Publicly To Fund AC2993 Phase IIIs

By Kim Coghill

Thursday, January 31, 2002
Amylin Pharmaceuticals Inc. started the second of three Phase III trials on AC2993, a compound designed to treat people with Type II diabetes by improving glucose control. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription